Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Robert Glanzman
Observed names:
Glanzman, Robert,
R Glanzman,
R. Glanzman,
R. L. Glanzman,
Robert L Glanzman
Observed institutions:
Roche (Switzerland),
Pfizer (United States),
University of California, Irvine,
University of Michigan,
University Hospital of Basel,
Utah State Historical Society,
Michigan Medicine,
Purdue Pharma (United States),
University of Pennsylvania
show all 9
ORCID:
0000-0002-6267-4006
Observed ORCID:
0000-0002-6267-4006
OpenAlex ID:
A5080151902
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
2011
·
Ludwig Kappos
, David Li
, et al.
·
The Lancet
·
744
Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials
2003
·
Miroslav Backonja
, Robert L Glanzman
·
Clinical Therapeutics
·
426
The role of optical coherence tomography in multiple sclerosis: Expert panel consensus
2007
·
Robert C. Sergott
, Elliot Frohman
, et al.
·
Journal of the Neurological Sciences
·
96
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
2021
·
Hans-Peter Hartung
, Tobias Derfuss
, et al.
·
Multiple Sclerosis Journal
·
88
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension
2023
·
Steve Vucic
, Parvathi Menon
, et al.
·
EClinicalMedicine
·
63
PDF
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment
2021
·
Steve Vucic
, Toby A. Ferguson
, et al.
·
Muscle & Nerve
·
61
Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials
2023
·
Jimin Ren
, Richard B. Dewey
, et al.
·
Journal of Nanobiotechnology
·
54
PDF
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
2021
·
Steve Vucic
, Matthew C Kiernan
, et al.
·
BMJ Open
·
52
Brachial plexopathy after botulinum toxin injections
1990
·
R. L. Glanzman
, D. J. Gelb
, et al.
·
Neurology
·
50
EDSS variability before randomization may limit treatment discovery in primary progressive MS
2012
·
Jiameng Zhang
, Emmanuelle Waubant
, et al.
·
Multiple Sclerosis Journal
·
20
CNM-Au8 in Amyotrophic Lateral Sclerosis
2025
·
Douglas Hayden
, Po-Ying Lai
, et al.
·
JAMA
·
17
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design
2016
·
Francois Curtin
, Herve Porchet
, et al.
·
Multiple Sclerosis and Related Disorders
·
16
Proof of concept studies for tissue-protective agents in multiple sclerosis
2009
·
LR Mehta
, SR Schwid
, et al.
·
Multiple Sclerosis Journal
·
9
Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)
2023
·
Sabrina Paganoni
, James Berry
, et al.
·
Neurology
·
5
Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: “Second International Workshop on Human Endogenous Retroviruses and Disease”, Washington DC, March 13th and 14th 2017
2017
·
David Kremer
, Robert Glanzman
, et al.
·
Multiple Sclerosis and Related Disorders
·
5
Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials
2024
·
Jimin Ren
, Richard B. Dewey
, et al.
·
Journal of Nanobiotechnology
·
3
VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis (PL5.005)
2023
·
Michael Barnett
, Heidi Beadnall
, et al.
·
Neurology
·
3
Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006)
2012
·
S. Hauser
, L. Kappos
, et al.
·
Neurology
·
3
On being a neurologist in industry
2012
·
David Leppert
, Robert Glanzman
·
Annals of Neurology
·
2
Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply
2012
·
Ludwig Kappos
, David Leppert
, et al.
·
The Lancet
·
2
PDF
Brain Target Engagement by CNM-Au8 in Parkinson’s Disease and Multiple Sclerosis: Integrated Imaging Results from the REPAIR-PD and REPAIR-MS Phase 2 Clinical Trials
2023
·
Jimin Ren
, Richard B. Dewey III
, et al.
·
Research Square
·
1
PDF
Improvements in the Power of Detecting Treatment Effect in a Primary Progressive Multiple Sclerosis (PPMS) Clinical Trial with the Use of Composite Disability Outcome Endpoints (P01.151)
2012
·
J. Zhang
, E. Waubant
, et al.
·
Neurology
·
1
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
2026
·
Samuel Klistorner
, Michael Hotchkin
, et al.
·
medRxiv
PDF
Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations (P8-8.004)
2023
·
James Berry
, Nicholas Maragakis
, et al.
·
Neurology
2322 Results of the Australian RESCUE-ALS trial: a phase 2, randomized, double-blind, placebo-controlled study of CNM-Au8 to slow disease progression in ALS
2022
·
Steve Vucic
, Parvathi Menon
, et al.
·
Abstracts
PDF
Show more works
View as search
Works count:
34
Citation count:
1,720
H-index:
12
I10-index:
12
Year
Topic
Type
